CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful. A limiting factor of this otherwise very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. CAR-T cells are one of the personalized cancer therapies and have been used in specialized centers in Europe since 2018. In this complex treatment, immune cells, or more precisely T cells, are taken from the blood of cancer patients, genetically engineered in the laboratory with a chimeric antigen receptor (CAR) and then re-administered.
Related Posts
Revolutionizing CAR-T Therapy: The CTLA-4 Tail Fusion Advantage
Chimeric antigen receptor (CAR)-T cells, although potent therapeutics, often face significant challenges in achieving their full efficacy. In this study, it is stated that the endocytic capability of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) cytoplasmic tail to revamp CAR functionality and significantly bolsters CAR-T cell effectiveness in live subjects. The molecular dynamics of reengineered CAR with […]
Vitiligo linked to lower skin cancer susceptibility
Vitiligo is a chronic skin condition in which the immune system attacks and destroys melanocytes, the cells that produce melanin, the pigment that gives skin its color. This results in white patches of skin appearing on different parts of the body. While vitiligo is not considered to be a precancerous condition, there is some evidence […]
Immune System Hack: How Our Ancestors’ Battles with Germs Gave Us Allergies
Ever wonder why you sneeze at pollen or get hives from shellfish? Blame your allergy-prone immune system, a legacy from our ancestors’ epic battles with germs! Back in the day, facing off against parasites and viruses was a full-time job. Our immune systems went into overdrive, learning to recognize and attack anything foreign. This hyper-vigilance […]